Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

NCT ID: NCT06199843

Last Updated: 2024-01-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 280 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-05
• Study Completion Date: 2024-12-31

Brief Summary

SBP is a common complication of cirrhotics with associated increased mortality. After first episode of SBP there is increased risk of again developing SBP, with increased chance of developing resistant organism. So after the first episode of SBP, prophylaxis for prevention of second episode onwards is mandatory and therefore Rifaximin or Norfloxacin is considered. It has been seen that apart from preventing SBP they have other benefits with negligible side effects and therefore it is to be seen what other benefits including mortality benefits these drugs can confer.

Detailed Description

Hypothesis:-Rifaximin will be more effective in decreasing the incidence of SBP in patients with cirrhosis and prior episode of SBP

AIM:-.To study the efficacy and safety of Rifaximin vs Norfloxacin in preventing incident SBP, preventing non-SBP infections, and improving transplant free survival in patients with cirrhosis and previous episode of SBP

Methodology Single centered Open labeled Randomized Controlled Trial

Randomization will be done by block randomization method taking block size as 10. Data will be entered in Microsoft Excel and will be analysed by SPSS Version 28.Categorical Data will be represented as frequency (%) and will be analysed using Chi square or Fisher Exact Test as appropriate.Continuous Data will be represented as Mean +/- SD and compared using Student T test or Mann Whitney as per normality conditions are met or not.Beside this an appropriate analysis like survival analysis will be carried out at the time of Data Analysis.P value <0.05 will be considered as significant.

Rescue therapy: To be given to patients who develop SBP while on secondary prophylaxis, these patients will initially be treated by iv medication in hospital settings followed by change in therapy.

• Patients in Rifaximin limb developing SBP will switch to Norfloxacin
• Patients in Norfloxacin limb developing SBP will switch to Rifaximin

Treatment Failure: Defined as development of SBP at end of 6 months or 1 year of treatment.

Study population: age >18 years with prior incident SBP

Study design: Randomised case controlled trial

Study period: 1year after ethical clearance

Sample size: 280 (140 in each arm)

Intervention: This RCT will be conducted at ILBS New Delhi Monitoring and assessment: Monitoring will be done forall the parameters of the objective. Documentation will be done for any adverse effects which will happen.

STATISTICAL ANALYSIS: Assuming incidence of SBP over 6 months is 4% in Rifaximin & 15% in Norfloxacin Alpha 5% and power 80%. Enrollment of 260 cases (130 in each arm). Assuming dropout rate 10%.Total study cases calculated as 280 (140 in each arm). Random allocation in each arm by block method taking 10 as block size

Conditions

Spontaneous Bacterial Peritonitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Rifaximin

Rifaximin 550 mg BD

Group Type: EXPERIMENTAL

Rifaximin

Intervention Type: DRUG

Rifaximin 550 mg BD

Norfloxacin

Norfloxacin 400 mg OD

Group Type: ACTIVE_COMPARATOR

Norfloxacin

Intervention Type: DRUG

Norfloxacin 400 mg OD

Interventions

Rifaximin

Rifaximin 550 mg BD

Intervention Type: DRUG

Norfloxacin

Norfloxacin 400 mg OD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age>18 years

2. Cirrhosis (of any etiology) with ascites

3. Prior incident SBP

Exclusion Criteria

1. Allergy to norfloxacin or rifaximin

2. Recent history of upper gastrointestinal bleed (UGIB) within 2 weeks

3. Patients with a history of multiple episodes of SBP

4. Patients with inoperable or not treatable HCC or other non-hepatic malignancy

5. Patients on immunosuppression

6. HIV infected

7. Post liver transplant

8. Recent (<6 months) abdominal surgery

9. Pregnant/lactating women

10. Other causes of ascites like tubercular or malignancy

11. Patients developing SBP on Norfloxcacin

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute of Liver and Biliary Sciences, India

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Dr Jaya Benjamin

New Delhi, National Capital Territory of Delhi, India

Countries

India

Central Contacts

Dr Jayashree Biswas, MD

Role: CONTACT

jayashreeb790@gmail.com

01146300000

Facility Contacts

Dr Jayshree Biswas, MD

Role: primary

jayashreeb790@gmail.com

01146300000

Other Identifiers

ILBS-SBP-03

Identifier Type: -

Identifier Source: org_study_id